Gadobenate Dimeglumine
Description
Name: Gadobenate Dimeglumine
Type: small molecule
Groups: approved
Indication: Gadobenate Dimeglumine is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for MRI of the heart, as well as and central nervous system in adults to visualize lesions with abnormal brain vascularity or abnormalities in the blood brain barrier, the brain, spine, or other associated tissues.
Accession Number: DB00743 ( APRD00989)
Description: Gadobenate Dimeglumine is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for visualizing the CNS and heart. In contrast to conventional extracellular fluid contrast agents, gadobenate dimeglumine is characterized by a weak and transient binding capacity to serum proteins. This binding leads to an increased relaxivity of gadobenate dimeglumine and, consequently, to a considerably increased signal intensity over that of other agents.
Structure:
Prescription Products:
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
Prescription Products:
International Brands
Brand Names
Brand Mixtures
Categories
Type: small molecule
Groups: approved
Indication: Gadobenate Dimeglumine is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for MRI of the heart, as well as and central nervous system in adults to visualize lesions with abnormal brain vascularity or abnormalities in the blood brain barrier, the brain, spine, or other associated tissues.
Accession Number: DB00743 ( APRD00989)
Description: Gadobenate Dimeglumine is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for visualizing the CNS and heart. In contrast to conventional extracellular fluid contrast agents, gadobenate dimeglumine is characterized by a weak and transient binding capacity to serum proteins. This binding leads to an increased relaxivity of gadobenate dimeglumine and, consequently, to a considerably increased signal intensity over that of other agents.
Structure:
Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Multihance | injection, solution | 529 mg/mL | intravenous | 23-11-2004 | US | |
| Multihance | injection, solution | 529 mg/mL | intravenous | 23-11-2004 | US | |
| Multihance | solution | 529 mg | intravenous | 28-10-2004 | Canada |
Generic Prescription Products: Not Available
Over the Counter Products: Not Available
Prescription Products:
| Name | Dosage | Strength | Route | Marketing Start | Marketing End | Country |
| Multihance | injection, solution | 529 mg/mL | intravenous | 23-11-2004 | US | |
| Multihance | injection, solution | 529 mg/mL | intravenous | 23-11-2004 | US | |
| Multihance | solution | 529 mg | intravenous | 28-10-2004 | Canada |
International Brands
- No Brands
Brand Names
- No Brands
Brand Mixtures
| Brand Name | Ingredients |
|---|---|
| Multihance | Gadobenate Dimeglumine |
| Multihance | Gadobenate Dimeglumine |
| Multihance | Gadobenate Dimeglumine |
| Brand Name | Ingredients |
|---|---|
| Multihance | Gadobenate Dimeglumine |
| Multihance | Gadobenate Dimeglumine |
| Multihance | Gadobenate Dimeglumine |
Categories
- Contrast Media
Pharmacology
Indication: Gadobenate Dimeglumine is an MRI contrast agent used primarily for MR imaging of the liver. It can also be used for MRI of the heart, as well as and central nervous system in adults to visualize lesions with abnormal brain vascularity or abnormalities in the blood brain barrier, the brain, spine, or other associated tissues.
Pharmacodynamics: Not Available
Mechanism of action: Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed, its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record 2 different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and the T2 (spin-spin or transverse relaxation time). In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, Gadobenate Dimeglumine shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, Gadobenate Dimeglumine primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Gadobenate Dimeglumine does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars).
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Plasma protein binding is low, weak, and transient.
Metabolism: Not Available
Route of elimination: Gadobenate ion is eliminated predominately via the kidneys, with 78% to 96% of an administered dose recovered in the urine.
Half life: 1 hour
Clearance: Not Available
Toxicity: Gadolinium-based radiocontrast agents like gadobenate dimeglumine are cytotoxic to renal cells. The toxic effects include apoptosis, cellular energy failure, disruption of calcium homeostasis, and disturbance of tubular cell polarity, and are thought to be linked to oxidative stress.
Affected organisms
SNP Mediated Adverse Drug Reactions
Pharmacodynamics: Not Available
Mechanism of action: Based on the behavior of protons when placed in a strong magnetic field, which is interpreted and transformed into images by magnetic resonance (MR) instruments. Paramagnetic agents have unpaired electrons that generate a magnetic field about 700 times larger than the proton's field, thus disturbing the proton's local magnetic field. When the local magnetic field around a proton is disturbed, its relaxation process is altered. MR images are based on proton density and proton relaxation dynamics. MR instruments can record 2 different relaxation processes, the T1 (spin-lattice or longitudinal relaxation time) and the T2 (spin-spin or transverse relaxation time). In magnetic resonance imaging (MRI), visualization of normal and pathological brain tissue depends in part on variations in the radiofrequency signal intensity that occur with changes in proton density, alteration of the T1, and variation in the T2. When placed in a magnetic field, Gadobenate Dimeglumine shortens both the T1 and the T2 relaxation times in tissues where it accumulates. At clinical doses, Gadobenate Dimeglumine primarily affects the T1 relaxation time, thus producing an increase in signal intensity. Gadobenate Dimeglumine does not cross the intact blood-brain barrier; therefore, it does not accumulate in normal brain tissue or in central nervous system (CNS) lesions that have not caused an abnormal blood-brain barrier (e.g., cysts, mature post-operative scars).
Absorption: Not Available
Volume of distribution: Not Available
Protein binding: Plasma protein binding is low, weak, and transient.
Metabolism: Not Available
Route of elimination: Gadobenate ion is eliminated predominately via the kidneys, with 78% to 96% of an administered dose recovered in the urine.
Half life: 1 hour
Clearance: Not Available
Toxicity: Gadolinium-based radiocontrast agents like gadobenate dimeglumine are cytotoxic to renal cells. The toxic effects include apoptosis, cellular energy failure, disruption of calcium homeostasis, and disturbance of tubular cell polarity, and are thought to be linked to oxidative stress.
Affected organisms
- Not Available
SNP Mediated Adverse Drug Reactions
- Not Available
Pharmacoeconomics
Manufacturers:
Packagers:
Dosage forms
Prices
Patents
- Bracco diagnostics inc
Packagers:
Dosage forms
| Form | Route | Strength |
|---|---|---|
| Injection, solution | intravenous | 529 mg/mL |
| Solution | intravenous | 529 mg |
| Form | Route | Strength |
|---|---|---|
| Injection, solution | intravenous | 529 mg/mL |
| Solution | intravenous | 529 mg |
Prices
| Unit description | Cost | Unit |
|---|---|---|
| Multihance 529 mg/ml vial | $6.87 | ml |
| Unit description | Cost | Unit |
|---|---|---|
| Multihance 529 mg/ml vial | $6.87 | ml |
Patents
| Country | Patent Number | Approved | Expires (estimated) |
|---|---|---|---|
| 4916246 | United States | 1995-04-10 | 2012-04-10 |
Interactions
Drug Interactions
Food Interactions:
| Drug | Interaction |
|---|---|
| Citalopram | Gadobenate Dimeglumine may increase the QTc-prolonging activities of Citalopram. |
| Dofetilide | Gadobenate Dimeglumine may increase the QTc-prolonging activities of Dofetilide. |
| Goserelin | Goserelin may increase the QTc-prolonging activities of Gadobenate Dimeglumine. |
| Ivabradine | Ivabradine may increase the QTc-prolonging activities of Gadobenate Dimeglumine. |
| Leuprolide | Leuprolide may increase the QTc-prolonging activities of Gadobenate Dimeglumine. |
| Mifepristone | Mifepristone may increase the QTc-prolonging activities of Gadobenate Dimeglumine. |
| Octreotide | Octreotide may increase the QTc-prolonging activities of Gadobenate Dimeglumine. |
| Drug | Interaction |
|---|---|
| Citalopram | Gadobenate Dimeglumine may increase the QTc-prolonging activities of Citalopram. |
| Dofetilide | Gadobenate Dimeglumine may increase the QTc-prolonging activities of Dofetilide. |
| Goserelin | Goserelin may increase the QTc-prolonging activities of Gadobenate Dimeglumine. |
| Ivabradine | Ivabradine may increase the QTc-prolonging activities of Gadobenate Dimeglumine. |
| Leuprolide | Leuprolide may increase the QTc-prolonging activities of Gadobenate Dimeglumine. |
| Mifepristone | Mifepristone may increase the QTc-prolonging activities of Gadobenate Dimeglumine. |
| Octreotide | Octreotide may increase the QTc-prolonging activities of Gadobenate Dimeglumine. |
Food Interactions:
- Not Available
Taxonomy
Kingdom: Not Available
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
substituent:
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
- Not Available
substituent:
- Not Available
References
Synthesis Reference: Pier Lucio Anelli, Pierfrancesco Morisini, Silvia Ceragioli, Fulvio Uggeri, Luciano Lattuada, Roberta Fretta, Aurelia Ferrigato, "Process for the Preparation of Gadobenate Dimeglumine Complex in a Solid Form." U.S. Patent US20120232151, issued September 13, 2012.
General Reference: # de Haen C, Cabrini M, Akhnana L, Ratti D, Calabi L, Gozzini L: Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S161-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10608412 # Morana G, Salviato E, Guarise A: Contrast agents for hepatic MRI. Cancer Imaging. 2007 Oct 1;7 Spec No A:S24-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17921081 # Vogl TJ, Pegios W, McMahon C, Balzer J, Waitzinger J, Pirovano G, Lissner J: Gadobenate dimeglumine--a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers. AJR Am J Roentgenol. 1992 Apr;158(4):887-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1546612 # Kirchin MA, Pirovano GP, Spinazzi A: Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol. 1998 Nov;33(11):798-809. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9818314 # Clement O, Siauve N, Cuenod CA, Vuillemin-Bodaghi V, Leconte I, Frija G: Mechanisms of action of liver contrast agents: impact for clinical use. J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S45-52. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10608397
External Links:
ATC Codes:
AHFS Codes:
MSDS: Download
General Reference: # de Haen C, Cabrini M, Akhnana L, Ratti D, Calabi L, Gozzini L: Gadobenate dimeglumine 0.5 M solution for injection (MultiHance) pharmaceutical formulation and physicochemical properties of a new magnetic resonance imaging contrast medium. J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S161-8. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10608412 # Morana G, Salviato E, Guarise A: Contrast agents for hepatic MRI. Cancer Imaging. 2007 Oct 1;7 Spec No A:S24-7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/17921081 # Vogl TJ, Pegios W, McMahon C, Balzer J, Waitzinger J, Pirovano G, Lissner J: Gadobenate dimeglumine--a new contrast agent for MR imaging: preliminary evaluation in healthy volunteers. AJR Am J Roentgenol. 1992 Apr;158(4):887-92. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/1546612 # Kirchin MA, Pirovano GP, Spinazzi A: Gadobenate dimeglumine (Gd-BOPTA). An overview. Invest Radiol. 1998 Nov;33(11):798-809. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9818314 # Clement O, Siauve N, Cuenod CA, Vuillemin-Bodaghi V, Leconte I, Frija G: Mechanisms of action of liver contrast agents: impact for clinical use. J Comput Assist Tomogr. 1999 Nov;23 Suppl 1:S45-52. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10608397
External Links:
| Resource | Link |
|---|
| Resource | Link |
|---|
ATC Codes:
- Array
AHFS Codes:
- 92:00.00
MSDS: Download